Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11844837,clearance,"Mean EMP clearance, estimated steady-state volume of distribution, and elimination half-life were 3.7 L/h, 10.6 L, and 3.7 hours, respectively.",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),[l] / [h],3.7,4509,DB01196,Estramustine
,11844837,steady-state volume of distribution,"Mean EMP clearance, estimated steady-state volume of distribution, and elimination half-life were 3.7 L/h, 10.6 L, and 3.7 hours, respectively.",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),l,10.6,4510,DB01196,Estramustine
,11844837,elimination half-life,"Mean EMP clearance, estimated steady-state volume of distribution, and elimination half-life were 3.7 L/h, 10.6 L, and 3.7 hours, respectively.",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),h,3.7,4511,DB01196,Estramustine
,11844837,Elimination half-lives,"Elimination half-lives of EoM and EaM were 110 hours and 64 hours, and peak plasma concentrations of these active metabolites exceeded 10 micromol/L after IV EMP doses greater-than-or-equal 2,000 mg/m(2).",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),h,110,4512,DB01196,Estramustine
,11844837,Elimination half-lives,"Elimination half-lives of EoM and EaM were 110 hours and 64 hours, and peak plasma concentrations of these active metabolites exceeded 10 micromol/L after IV EMP doses greater-than-or-equal 2,000 mg/m(2).",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),h,64,4513,DB01196,Estramustine
exceeded,11844837,peak plasma concentrations,"Elimination half-lives of EoM and EaM were 110 hours and 64 hours, and peak plasma concentrations of these active metabolites exceeded 10 micromol/L after IV EMP doses greater-than-or-equal 2,000 mg/m(2).",Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11844837/),[μM] / [l],10,4514,DB01196,Estramustine
,6714283,volumes of distribution,"The mean volumes of distribution were small, being 43 and 108 ml/kg for the central and peripheral compartments, respectively.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),[ml] / [kg],43,90227,DB01196,Estramustine
,6714283,volumes of distribution,"The mean volumes of distribution were small, being 43 and 108 ml/kg for the central and peripheral compartments, respectively.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),[ml] / [kg],108,90228,DB01196,Estramustine
,6714283,plasma clearance,"The plasma clearance was 64 ml/kg/h, and the half-lives of the two phases were 0.16 and 1.27 h.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),[ml] / [h·kg],64,90229,DB01196,Estramustine
,6714283,half-lives,"The plasma clearance was 64 ml/kg/h, and the half-lives of the two phases were 0.16 and 1.27 h.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),h,0.16,90230,DB01196,Estramustine
,6714283,half-lives,"The plasma clearance was 64 ml/kg/h, and the half-lives of the two phases were 0.16 and 1.27 h.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),h,1.27,90231,DB01196,Estramustine
,6714283,relative bioavailability,"The relative bioavailability of estromustine after administration of EMP-capsules was 44%, which reflects incomplete absorption of EMP rather than first-pass metabolism of estromustine.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),%,44,90232,DB01196,Estramustine
,6714283,terminal half-life,"The terminal half-life of estromustine was 10-20 h, which suggests that EMP might be given once or twice a day.",Pharmacokinetics of estramustine phosphate (Estracyt) in prostatic cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6714283/),h,10-20,90233,DB01196,Estramustine
,15671557,survival,Median survival was 14.6 months.,"A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15671557/),month,14.6,171334,DB01196,Estramustine
,12796374,area under the curve,Patients with advanced prostate cancer (castrate and noncastrate) were administered escalating doses of weekly 1-h infusion of i.v. EMP (500-1000-1500 mg/m(2)) in combination with weekly paclitaxel (100 mg/m(2) over 1 h) and i.v. carboplatin (area under the curve 6 mg/ml-min every 4 weeks).,Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12796374/),[mg] / [ml-min],6,188636,DB01196,Estramustine
,8884875,AUC,The AUC for one dose interval (12 hr) was also significantly higher for estramustine phosphate with clodronate than without clodronate.,Effect of concomitant administration of clodronate and estramustine phosphate on their bioavailability in patients with metastasized prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884875/),h,12,271810,DB01196,Estramustine
,16568471,time to progression,"A partial objective tumor response was demonstrated in 1 of 13 evaluable patients (7.7%) in each dose group; the median time to progression for both doses combined was 185 days (range, 28-233 days).",Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16568471/),d,185,272289,DB01196,Estramustine
,10071290,overall 50%,"The overall 50% PSA response rate was 63% (95% confidence interval [CI], 28% to 81%).",Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071290/),%,63,273724,DB01196,Estramustine
,10071290,area under the curve,"At 80 mg/m2, the measured area under the curve was 8.37 (standard deviation, 0.724), which was significantly higher than the previously reported values.",Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071290/),,8.37,273725,DB01196,Estramustine
